JFG
GALT icon

Jefferies Financial Group’s Galectin Therapeutics GALT Stock Holding History

Jefferies Financial Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34K Sell
12,188
-4,247
-26% -$12.9K ﹤0.01% 1661
2025
Q4 		$68.4K Sell
16,435
-865
-5% -$4.55K ﹤0.01% 1741
2025
Q3 		$73.3K Buy
+17,300
New +$65.1K ﹤0.01% 1368

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Jefferies Financial Group's GALT Position: Q1 2026 in Review

Jefferies Financial Group reduced its Galectin Therapeutics (GALT) stake by 26% in Q1 2026, selling an estimated $12.9K and leaving 12,188 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

Jefferies Financial Group first reported a position in GALT in Q3 2025 and has held it in 3 quarters since. The position peaked at $73.3K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Jefferies Financial Group held 12,188 shares of Galectin Therapeutics worth $34K as of Q1 2026.
  • Jefferies Financial Group sold 4,247 Galectin Therapeutics shares in Q1 2026, an estimated $12.9K.
  • Galectin Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1661 holding.
  • Jefferies Financial Group first reported a position in Galectin Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jefferies Financial Group's Galectin Therapeutics position peaked at $73.3K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.